ADA and myeloid sarcoma: These two assays can be used to detect the development of binding and neutralizing alemtuzumab-specific ADA, as seen in an individual with MS (Figure 4) who stopped depleting lymphocytes and exhibited breakthrough disease activity as indicated by new lesion formation (Figure 4A).